A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.
A recent study compared the safety and efficacy of multiple chemotherapy agents in treating advanced liposarcoma.
A recent study compared the effectiveness of stereotactic ablative body radiotherapy with conventional full fractionated radiotherapy in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer.
A recent study suggests that improvements in Hodgkin lymphoma treatment—including smaller radiation fields—have led to higher cure rates and lower rates of toxicity.
Patients with a certain B-cell malignancy and abnormal liver function tests at diagnosis are at risk of shorter overall survival compared with those who have normal liver function.
A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer.
While the overall risk of secondary cancers after Kaposi sarcoma has declined in people with HIV/AIDS, clinicians should be aware that certain cancers are becoming increasingly common in the highly active antiretroviral therapy era compared with the pre-HAART era.
Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse.
Many patients with localized prostate cancer don’t understand the differences between their treatment options, a new study suggests.
A recent survey has revealed that precision medicine programs are gaining ground as a critical investment within oncology health care systems.